George Elston - Feb 9, 2023 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Financial Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Feb 9, 2023
Transactions value $
$0
Form type
4
Date filed
2/13/2023, 03:58 PM
Previous filing
Jan 10, 2023
Next filing
May 30, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +5.83K +47.36% $0.00 18.1K Feb 9, 2023 Direct F1
transaction EYPT Common Stock Options Exercise $0 +4.97K +27.37% $0.00 23.1K Feb 9, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -5.83K -33.33% $0.00 11.7K Feb 9, 2023 Common Stock 5.83K $0.00 Direct F2
transaction EYPT Restricted Stock Units Options Exercise $0 -4.97K -50% $0.00 4.97K Feb 9, 2023 Common Stock 4.97K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 887 shares acquired on 7/31/22 and 2,745 shares acquired on January 31, 2023, pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
F2 The restricted stock units vests in three ratable annual installments beginning February 9, 2023.